David J. McClain - Concepedia

Author

David J. McClain

United States Army Medical Research Institute of Infectious Diseases

Also Known As

D. J. McClain, David J. McClain, David McClain, David J. McClain

Publications

590

Citations

H-Index

Concepts

All Affiliations

United States Army Medical Research Institute of Infectious Diseases University of Massachusetts Chan Medical School

About

David J. McClain is an author at United States Army Medical Research Institute of Infectious Diseases specializing in medicine, flavivirus, and virology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	177
2	Emergency Medicine	1	1	79
3	Immunology	1	1	42
4	Drug Resistance	1	1	79
5	Vaccine Development	1	1	42

David J. McClain

Publications

555

Citations

H-Index

Page 1

	Year	Citations
Immunologic Interference from Sequential Administration of Live Attenuated Alphavirus Vaccines David J. McClain, Phillip R. Pittman, Helen H. Ramsburg, The Journal of Infectious Diseases	1998	113
Primary Induction of Human CD8<sup>+</sup>Cytotoxic T Lymphocytes and Interferon‐γ–Producing T Cells after Smallpox Vaccination Francis A. Ennis, John Cruz, Walter E. Demkowicz, The Journal of Infectious Diseases	2002	109
Clinical evaluation of a vaccinia-vectored Hantaan virus vaccine David J. McClain, P L Summers, Stephen A. Harrison, Journal of Medical Virology	2000	80
Clinical Recognition and Management of Patients Exposed to Biological Warfare Agents David R. Franz, Peter B. Jahrling, David J. McClain, Clinics in Laboratory Medicine Biologic AgentHealthcare-associated InfectionBiological Warfare AgentsChemical Warfare AgentChemical Agent	2001	79
Immunologic Responses to Vaccinia Vaccines Administered by Different Parenteral Routes David J. McClain, Shannon M. Harrison, Curtis Yeager, The Journal of Infectious Diseases	1997	76
Alphaviruses (Togaviridae) and Flaviviruses (Flaviviridae) Alan Schmaljohn, David J. McClain Europe PMC (PubMed Central) Emergent VirusVirologyVirus ClassificationVirus PhylogenyMedicine	1996	56
Safety and immunogenicity of a mutagenized, live attenuated Rift Valley fever vaccine, MP-12, in a Phase 1 dose escalation and route comparison study in humans Phillip R. Pittman, David J. McClain, Xiaofei Quinn, Vaccine VaccinationVaccine SafetyVaccine DevelopmentDose EscalationVaccine Target	2015	42

Page 1